PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study

Related articles

1. Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective Analysis

   This article has 13 authors:

   1. Lucia Motta
   2. Francesca Molinari
   3. Jana Pankovics
   4. Benjamin Pedrazzini
   5. Alexandra Valera
   6. Samantha Epistolio
   7. Luca Giudici
   8. Stefania Freguia
   9. Miriam Patella
   10. Martina Imbimbo
   11. Giovanna Schiavone
   12. Milo Frattini
   13. Patrizia Froesch

2. Effects of Concomitant Medications on the Therapeutic Effectiveness of PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

   This article has 11 authors:

   1. Yue Shen
   2. Jie-Qi Chen
   3. Zhen Yu
   4. Zhi-Lan Lin
   5. Lei Cao
   6. Hui-Zhen Li
   7. Yue-Qin Li
   8. Ying-Cai Meng
   9. Bin Li
   10. Juan Chen
   11. Xiang-Ping Li

3. Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma

   This article has 11 authors:

   1. Pushan Dasgupta
   2. Heather Lin
   3. Gayatri Kumar
   4. Zaid Soomro
   5. Max M. Ayala
   6. Edwin R. Parra
   7. Shiao-Pei Weathers
   8. Frederick F. Lang
   9. Krishna P. Bhat
   10. John de Groot
   11. Nazanin K. Majd